What Dose Did Ashwagandha Trials Actually Use

The extract problem comes first

Withanolides are the compounds the trials measured, and their concentration in raw root is low and variable. Every trial with a clean result used a standardized extract, meaning a product processed to contain a stated percentage of withanolides.

Two extracts dominate the literature:

Extract	Standardization	Trial doses	Derived from
KSM-66	about 5% withanolides	300 to 600 mg per day	Root only
Sensoril	10% or more withanolides	125 to 250 mg per day	Root and leaf

They aren't interchangeable. A 300 mg dose of KSM-66 delivers roughly 15 mg of withanolides. A 300 mg dose of Sensoril delivers roughly 30 mg. Shopping by total milligrams without checking the extract name compares two different products.

Generic ashwagandha root powder, the cheapest option on the shelf, has no trial record at any dose. That doesn't make it useless. It makes it untested.

The dose that the cortisol trials used

Chandrasekhar and colleagues, publishing in the Indian Journal of Psychological Medicine in 2012, is the study most of the field builds on. Sixty-four adults with a history of chronic stress received 300 mg of KSM-66 twice daily, 600 mg total, or placebo, for 60 days.

Serum cortisol fell 27.9 percent in the treatment group against 7.9 percent with placebo. Scores on the Perceived Stress Scale fell alongside it. C-reactive protein, an inflammation marker, also declined.

Subsequent trials landed in a consistent band. A 2019 trial of a high-concentration extract found dose-dependent cortisol reductions at 250 mg and 600 mg per day in healthy but stressed adults. A 2019 trial in Medicine measured a 23 percent morning cortisol reduction on 240 mg of Sensoril over eight weeks. Reviews of the cortisol literature describe reductions between 14 and 32 percent, concentrated in people who started high.

The pattern matters more than any single number. Ashwagandha's measured effect is on elevated cortisol. Trials in unstressed people with normal cortisol show little change, which fits a regulatory mechanism rather than a suppressive one.

The sleep and anxiety trials

The dose range repeats. Langade and colleagues in 2019 gave 300 mg twice daily of KSM-66 to 60 adults with insomnia and anxiety for 10 weeks and measured improvements in sleep onset latency and total sleep time. A 2021 trial using 120 mg per day of a high-concentration extract for six weeks reported large subjective sleep quality improvements in healthy adults with poor sleep.

The 120 mg result is worth pausing on, because it's a fifth of the 600 mg protocol and the extract was concentrated. Concentration explains part of it. Subjective endpoints explain the rest. Sleep quality scores are soft measurements, and soft measurements move more easily than blood values.

How long the trials ran

Six to twelve weeks, almost uniformly. Cortisol effects appeared around weeks four to eight. There is no long-term trial of ashwagandha at these doses, which means there's no trial record supporting years of continuous use.

That's a real gap, and it's the answer to "can I take this forever" being nobody's business to promise.

The funding question

Here's the part the marketing skips. KSM-66 trials were largely funded by Ixoreal Biomed, which sells KSM-66. Sensoril trials were funded by Natreon, which sells Sensoril. The investigators are frequently employees or consultants.

Manufacturer funding doesn't automatically corrupt a randomized placebo-controlled trial. The cortisol measurements are objective, the designs are sound, and negative results did get published. But the combination of one funding source per extract, no independent replication of the flagship trials, and a large market waiting for a positive result is exactly the configuration where independent verification earns its keep.

The honest position: the signal is consistent, plausibly mechanistic, and unreplicated by anyone without a stake in the product.

Safety notes attached to the dose

The trial doses were well tolerated. Headache and drowsiness appeared at rates similar to placebo.

Liver injury is the exception worth knowing about. Case reports of drug-induced liver injury linked to ashwagandha have accumulated in pharmacovigilance databases, typically at higher-than-trial doses and often in multi-ingredient products. They're rare against the size of the exposed population, and they're a reason not to exceed trial doses casually.

Thyroid effects are documented. Trials in subclinical hypothyroidism showed increased T3 and T4 on 600 mg per day, which is a measured hormone change. Anyone on thyroid medication should treat that as an interaction to discuss, not a trivia point.

Pregnancy is a clear avoid. Traditional use and animal data both point away from it.

Frequently asked questions

Is 600 mg better than 300 mg?

The dose-response data is limited, and at least one trial found cortisol effects at 250 mg of a concentrated extract. Starting at 300 mg of a named 5 percent extract and reassessing at eight weeks covers what the trials actually support.

Can I take it in the morning?

The trials split doses morning and evening without testing timing as a variable. There's no trial evidence that one time of day is superior.

What if my bottle says 1,000 mg of root?

That's raw powder, not the standardized extract the trials used, and its withanolide content isn't stated. The 1,000 mg number doesn't translate into a trial dose.

Does it interact with my thyroid medication?

Possibly. Trials measured increases in thyroid hormones. This is a conversation for the prescriber managing the medication, with the bottle on the desk.

How do I know which extract I have?

The label names it if it's there. KSM-66, Sensoril, and Shoden are trademarked names that appear on the front panel. If the label says only "ashwagandha root extract 500 mg" with no withanolide percentage, you don't know what you're holding.

---

This article is for general information only and does not constitute medical advice. Statements about dietary supplements have not been evaluated by the Food and Drug Administration and are not intended to diagnose, treat, cure, or prevent any disease. Talk with your health care provider before starting any supplement, especially if you take thyroid medication, are pregnant, or have a liver condition.

Sources

• Chandrasekhar K et al., A prospective, randomized double-blind, placebo-controlled study of a high-concentration full-spectrum extract of ashwagandha root in reducing stress and anxiety, Indian J Psychol Med 2012
• Langade D et al., Efficacy and safety of ashwagandha root extract in insomnia and anxiety, Cureus 2019
• Salve J et al., Adaptogenic and anxiolytic effects of ashwagandha root extract in healthy adults, Cureus 2019
• Lopresti AL et al., An investigation into the stress-relieving and pharmacological actions of an ashwagandha extract, Medicine 2019
• LiverTox: Ashwagandha, National Institute of Diabetes and Digestive and Kidney Diseases
• NIH Office of Dietary Supplements, Ashwagandha consumer fact sheet